Global Small Molecule Targeted Cancer Therapy Market, By Type (Small Molecules, Small Molecule Drug Conjugates, and Monoclonal Antibodies), Application (Lymphoma, Melanoma, Multiple Myeloma, Breast Cancer, Prostate Cancer, and Other Cancers), End User (Hospitals, Cancer and Radiation Therapy Centers, and Clinics) - Industry Trends and Forecast to 2030.
Small Molecule Targeted Cancer Therapy Market Analysis and Size
Rapid advancements in drug discovery and development have led to identifying and developing a wide range of small-molecule targeted therapies. These therapies target specific molecules or pathways involved in cancer growth and progression, offering enhanced efficacy and reduced side effects compared to traditional chemotherapy.
Data Bridge Market Research analyses that the global small molecule targeted cancer therapy market which was USD 75,960.00 Million in 2022, would rocket up to USD 124,772.24 Million by 2030 and is expected to undergo a CAGR of 6.4% during the forecast period. “Small Molecules” dominates type segment of the global small molecule targeted cancer therapy market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Small Molecule Targeted Cancer Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Small Molecules, Small Molecule Drug Conjugates, and Monoclonal Antibodies), Application (Lymphoma, Melanoma, Multiple Myeloma, Breast Cancer, Prostate Cancer, and Other Cancers), End User (Hospitals, Cancer and Radiation Therapy Centers, and Clinics)
|
|
Countries Covered
|
(U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa)
|
|
Market Players Covered
|
Boehringer Ingelheim International GmbH (Germany), Abbott Laboratories. (U.S.), CYTOKINETICS, INC.(U.S.) Bayer AG (Germany), GlaxoSmithKline plc. (UK), AstraZeneca (UK), AVEO Pharmaceuticals, Inc.(U.S.), Johnson & Johnson Services, Inc.(U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Pfizer Inc.(U.S.), Allergan (Ireland), Merck Sharp & Dohme Corp.(U.S.), Gilead Sciences, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Amgen Inc.(U.S.), AbbVie Inc.(U.S.), Eli Lilly and Company (U.S.), and Bausch Health (Canada)
|
|
Market Opportunities
|
|
Market Definition
The global small molecule targeted cancer therapy market is the pharmaceutical industry segment focused on the development, manufacturing, and commercialization of small molecule drugs specifically designed to target and inhibit specific molecules or pathways involved in cancer growth and progression. These drugs, also known as targeted therapies or molecularly targeted drugs, are designed to interfere with specific cellular processes that contribute to tumor growth, survival, and metastasis.
Unlike traditional chemotherapy drugs that can affect cancer cells and normal cells, small molecule targeted therapies target cancer cells while minimizing damage to healthy cells selectively. They work by interacting with specific molecular targets, such as proteins, enzymes, or signaling pathways, that play a critical role in tumor development and progression.
Global Small Molecule Targeted Cancer Therapy Market Dynamics
Drivers
- Increasing cancer incidence
The rising prevalence of cancer worldwide is a major driver for the small molecule targeted cancer therapy market. As the global burden of cancer grows, there is an increasing need for more effective and personalized treatment options.
- Growing demand for personalized medicine
There is a growing demand for personalized medicine in cancer treatment, where therapies are tailored to an individual's specific molecular profile. Small molecule targeted therapies offer the potential for more precise and personalized treatment approaches, addressing the unique characteristics of each patient's cancer.
Opportunity
-
Development of biomarkers
Biomarkers play a crucial role in patient selection and treatment response monitoring. Developing reliable biomarkers predicting response to targeted therapies can improve patient outcomes and optimize treatment selection.
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising number of market players will further expand the market's growth rate in the future.
Restraint/Challenge
- Toxicity and side effects
Although targeted therapies are designed to be more selective, they can still have side effects. Off-target effects or on-target but unintended effects can lead to toxicity and adverse reactions. Managing the balance between efficacy and tolerability remains an ongoing challenge.
On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the supply chain industry disruption can challenge the market’s growth. Also, lack of favorable reimbursement scenarios, technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.
This global small molecule targeted cancer therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global small molecule targeted cancer therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In 2021, Roche received accelerated FDA approval for Rozlytrek (entrectinib) as a treatment for certain types of solid tumors with NTRK gene fusions
- In 2021, Novartis received FDA approval for Tabrecta (capmatinib) as a targeted therapy for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations
Global Small Molecule Targeted Cancer Therapy Market Scope
The global small molecule targeted cancer therapy market is segmented on the basis of type, application, and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Small Molecules
- Small Molecule Drug Conjugates
- Monoclonal Antibodies
Application
- Lymphoma
- Melanoma
- Multiple Myeloma
- Breast Cancer
- Prostate Cancer
- Other Cancers
End User
- Hospitals
- Cancer and Radiation Therapy Centers
- Clinics
Global Small Molecule Targeted Cancer Therapy Market Regional Analysis/Insights
The global small molecule targeted cancer therapy market is analyzed, and market size insights and trends are provided by product, application, and end-user as referenced above.
The countries covered in the global small molecule targeted cancer therapy market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa.
North America is expected to dominate the market due to factors including rising healthcare costs, increased R & D, and trending technological advancements.
Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favorable government initiatives in the region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global small molecule targeted cancer therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Small Molecule Targeted Cancer Therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Small Molecule Targeted Cancer Therapy market. The data is available for the historic period 2015-2021
Competitive Landscape and Small Molecule Targeted Cancer Therapy Market Share Analysis
The global small molecule targeted cancer therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global small molecule targeted cancer therapy market are:
- Boehringer Ingelheim International GmbH (Germany)
- Abbott Laboratories. (U.S.)
- CYTOKINETICS, INC.(U.S.)
- Bayer AG (Germany)
- GlaxoSmithKline plc. (UK)
- AstraZeneca (UK)
- AVEO Pharmaceuticals, Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc. (U.S.)
- Allergan (Ireland)
- Merck Sharp & Dohme Corp. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Sanofi (France)
- Amgen Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Bausch Health (Canada)
SKU-